Supportive care is an important component of mastocytosis management. While treatment plans vary based on age and disease severity, addressing side effects, maintaining daily function and improving quality of life remain central goals across all forms of the condition. Achieving effective supportive care requires ongoing communication between patients and specialists. It can involve personalised medication regimens, strategies to manage disease symptoms and minimise medication side effects and allied health support to bolster physical and psychological health.32
Paediatric mastocytosis
In most cases, limited supportive care is required for children with mastocytosis. However, additional support may be helpful in addressing the emotional and developmental impacts of managing chronic symptoms during early life. In some cases, play therapy or psychological services may be useful. Play therapy can help children process their experiences, build coping skills, and remain engaged in developmentally-appropriate activities, even when adjustments are needed as part of their overall disease management.69,70
For children who carry adrenaline autoinjectors, supportive care should include age-appropriate education on their safe use, as well as clear language to seek help from adults during an emergency. Families and school staff should know how to recognise symptoms of anaphylaxis and respond effectively. Empowering children with a sense of confidence and understanding around their condition can help reduce anxiety and improve overall safety.70
Note: Supplemental resources which may support children and their carers through navigation of anaphylaxis risks in early childhood and primary school can be found on the Allergy Aware website. Resources for parents of teenagers and young adults can be found on Allergy250k.
Non-advanced mastocytosis
Non-advanced mastocytosis accounts for the majority of SM cases, with indolent systemic mastocytosis (ISM), a non-advanced variant, representing approximately 90 per cent of all SM cases.71 ISM is characterised by a wide spectrum of symptoms, typically without evidence of organ damage, and is associated with a life expectancy close to that of the global population.7
Non-advanced mastocytosis types are rarely life-limiting.22,23 However, symptoms can significantly influence a patient’s quality of life.72,73 In addition to disease-related symptoms, some of the daily or as-needed medications used in mastocytosis may cause side effects which vary depending on the type of treatment, dosage and individual sensitivities.9,72,74 In some cases, side effects may overlap with disease symptoms, making them difficult to distinguish.74
Supportive care is a key part of long-term mastocytosis management. It focuses on improving day-to-day well-being, addressing symptoms, managing side effects and reducing triggers contributing to flares. This often requires an individually tailored approach, which may involve specialists, general practitioners and allied health professionals.
Different aspects of quality of life carry different levels of importance for each patient.75 Where appropriate, and when adjustments do not compromise safety or overall treatment outcomes, patients should feel empowered to advocate for their personal well-being goals during specialist reviews. For some, this may include seeking to avoid medications that cause excessive sedation due to their impact on work or daily functioning. Others may prioritise avoiding treatments that affect confidence or comfort in social situations, such as those associated with hair thinning or weight changes.
Conversely, some patients may be willing to utilise specific therapies alongside supportive strategies to reduce or manage side effects.74,75 This may include medications to counter sedation, address nausea, or access to allied health supports that help maintain function and independence. In some cases, physiotherapy, exercise physiology, or psychological support may also be helpful, particularly when symptoms impact mobility, cognitive function, or emotional well-being.
As mastocytosis symptoms may also overlap with the presentation of medication side effects, patients are strongly encouraged to discuss possible side effects and quality of life concerns with their treating specialist and general practitioner throughout their care.74 Prompt reporting and candid discussion about the impact of new or worsening symptoms can support timely investigations, reduce potential risks, and allow for adaptive supportive care strategies to maintain or improve quality of life as patients’ goals and needs evolve.
Note: You can read more about general medication and side effects on the NPS Medicinewise website.
Advanced systemic mastocytosis (AdvSM) and mast cell leukemia (MCL)
In advanced forms of systemic mastocytosis, including aggressive systemic mastocytosis, mastocytosis with an associated haematological neoplasm (SM-AHN) and MCL, supportive care becomes a central component of treatment.76
In these disease subtypes, palliative care may be recommended as it can play an essential role in improving comfort and quality of life. Palliative care refers to any approach to reduce symptoms and side effects, support emotional and psychosocial wellbeing and maintain daily functioning. It is appropriate at any stage of advanced disease and can be provided alongside active treatments, such as chemotherapy or targeted therapies.77
Palliative care does not hasten death. Rather, it helps patients and their families navigate the physical and emotional challenges of living with serious illness. Interventions may include pain relief, anti-nausea therapies, psychological or spiritual support, nutritional planning, medication review and access to allied health professionals. Depending on regional accessibility and patient preferences, it may be delivered in hospital settings, outpatient services, or at home.77
Early referrals to palliative care can support better symptom control, reduce unplanned hospital visits, and ensure that care remains aligned with the patient’s values and goals. Patients with advanced disease subtypes are encouraged to speak with their treating specialist about if a referral is appropriate to manage their disease.77
Patient and carer crisis support
While TAMS provides general information on mast cell activation disorders, including resources to support patient understanding and discussions with their doctors, we are unable to offer independent medical advice or emotional support.
If the above information has caused distress, please do not hesitate to seek support.
- Lifeline is available 24/7 to provide compassionate support for people in crisis by phone on 13 11 14.
- Griefline offers services, including support for processing grief related to a new diagnosis – whether your own or a loved one’s. You can call 1300 845 745 between 8 am and 8 pm, 7 days a week (AEST/AEDT) or request a callback at a time that suits you.
For non-emergency support with a suspected or confirmed rare disease, you can also connect with the RARE Helpline at 0499 549 629, operating Monday to Friday, 9 am to 5 pm (AEST/AEDT), or visit the RARE Helpline website.
Carers can also seek support from the Carer Gateway Counselling Service, a free service designed to assist carers. Professional counsellors are available weekdays from 8 am to 6 pm to provide guidance and support. You can request a callback by filling in your details on their website, and they will call you back within one business day. Alternatively, you can call 1800 422 737 and select Option 2 to speak with their team.
Discover more mental health support services in Australia and Aotearoa New Zealand.
Disclaimer
Last updated: 12 December 2025
Please note that this information is provided for general educational purposes only and does not replace medical advice, nor should it be used in place of consultation with a qualified health professional. While care has been taken to reflect current information based on reputable scientific source material at the time of writing, and TAMS will continue to update information periodically, omissions or inconsistencies may occur as scientific knowledge evolves.
